Surveying Antimicrobial Resistance: The New Complexity of the Problem
The introduction of penicillin in the 1940s, the start of the antibiotics era, has been recognized as one of the greatest advances in therapeutic medicine. However, according to the World Health Organization (WHO), antimicrobial resistant infections are now an increasing worldwide public health threat and a post-antibiotic era is imminent when even common infections and minor injuries could be fatal. Antimicrobial resistance (AMR) reduces the effectiveness of treatment and patients remain infected for a longer period, thereby increasing the potential to spread resistant microorganisms to others, according to WHO. Without effective antimicrobials to counter and prevent infections, other major achievements in modern medicine, such as organ transplantation, cancer chemotherapy and major surgery, risk being compromised. According to The State of the World’s Antibiotics, two-thirds of the 100,000 tons of antibiotics produced globally each year are used in animal husbandry, and of the 27 antimicrobials used in animals, 18 are also used for human medicine. In terms of global sales in 2009, the top three antimicrobial classes for use in animals were macrolides, penicillins and tetracyclines, all of which are categorized as being critical for human medicine. The growth of global trade and travel allows resistant microorganisms to be spread rapidly to distant countries and continents, which threatens health security and risks damaging trade and economics.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.